Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 71 Debt-to-Equity is 0.20 as of Jun. 2026, which is 54% above its 10-year median of 0.13. GuruFocus rates CHIX:VITRS with a GF Score™ of 71/100 and a GF Value™ of kr179.44 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 696 Medical Devices & Instruments companies, Vitrolife AB ranks better than 54.45% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Vitrolife AB's Debt-to-Equity or its related term are showing as below:
CHIX:VITRs'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 0.2
Current: 0.2
During the past 13 years, the highest Debt-to-Equity Ratio of Vitrolife AB was 0.20. The lowest was 0.01. And the median was 0.13.
CHIX:VITRs's Debt-to-Equity is ranked better than 54.45% of 696
companies
in the Medical Devices & Instruments industry
Industry Median: 0.24
vs CHIX:VITRs: 0.20
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Vitrolife AB Debt-to-Equity Related Terms
Vitrolife AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VITRS vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Vitrolife AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (CHIX:VITRS) has a Debt-to-Equity of 0.20 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vitrolife AB and its competitors. This is 54% above median its historical median of 0.13. Over the past decade, Vitrolife AB's Debt-to-Equity has ranged from 0.01 to 0.20. According to the industry distribution chart, Vitrolife AB ranks #317 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 45.5%.
Is Vitrolife AB's Debt-to-Equity too high?
Vitrolife AB's current Debt-to-Equity of 0.20 is 54% above median its 10-year median of 0.13. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.20. The Medical Devices & Instruments industry median Debt-to-Equity is 0.24. Vitrolife AB's value of 0.20 is 16.7% below this industry median. Based on the distribution chart, Vitrolife AB ranks #317 out of 696 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #317 out of 696 companies for Debt-to-Equity. This puts Vitrolife AB in the upper half of its industry. The industry median Debt-to-Equity is 0.24. Vitrolife AB's value of 0.20 is 16.7% below this benchmark. Historically, Vitrolife AB's own Debt-to-Equity has ranged from 0.01 to 0.20 over the past decade. While the company's 10-year median is 0.13 vs. the industry median of 0.24, Vitrolife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.24, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Debt-to-Equity of 0.20 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Debt-to-Equity is 0.20, which is 54% above median its own 10-year median of 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr179.44, compared to a current price of kr86.38 — trading 51.9% below its estimated fair value. The current Debt-to-Equity is 0.20, which is 54% above median its 10-year median of 0.13 and 16.7% below the Medical Devices & Instruments industry median of 0.24. Vitrolife AB's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Debt-to-Equity is 0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr86.38 is trading 51.9% below its estimated GF Value™ of kr179.44.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
Debt-to-Equity: 0.20 (54% above median its 10-year median of 0.13)
GF Value™: kr179.44 vs. price of kr86.38 (51.9% below fair value)
Industry Position: 16.7% below the Medical Devices & Instruments median (#317 of 696)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
71GF Score
Get the complete analysis for CHIX:VITRS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
